Prof. Dr. med. Christian la Fougère
Medical Director and Chair for Nuclear Medicine and Clinical Molecular Imaging
University Hospital Tübingen
72076 Tübingen, Germany
Molecular imaging (MI) is paving the way for precision and personalized medicine. Molecular imaging techniques using radiolabeled pharmaceuticals and positron-emission-tomography (PET) are increasingly used for the assessment of pathobiochemical and pathophysiological changes in oncology and neurology. We aim to test and to implement new molecular imaging probes for different oncological and neurological diseases, in order to obtain a better characterization of the underlying molecular changes in vivo.
New generation hybrid PET-MR scanner enable the simultaneous acquisition of molecular (PET) as well as morphological and functional (chemical shifts, flow, diffusion, blood oxygenation and perfusion) changes (MR) in vivo, that might give new insights in the oncological processes. We aim to use those multi-parametric imaging techniques in order to provide an insight in physiological (adaptive) as well as pathophysiological changes, which might lead to an individualized treatment stratification for our patients in the future.
- Multimodal and Multiparametric imaging with PET/MR for treatment stratification, therapy planning and therapy monitoring in brain tumors
- Translational use of new probes for PET imaging in oncology and neurology
- Neuroreceptor-Imaging with SPECT, PET and PET/MR in neurodegenerative and psychiatric diseases
- Implementation of new theranostic approaches into the clinic.
- Assessment of brain plasticity by means of multiparametric PET and MR imaging
- Brain activation studies with PET
Joint Research Projects
2017 – 2020
Else-Kröner-Fresenius-Forschungskolleg “Therapieresistenz solider Tumore“